TD Cowen Keeps Their Buy Rating on Dianthus Therapeutics (DNTH)

Werber covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Argenx Se, and Amgen. According to TipRanks, Werber has an average return of 23.3% and a 57.40% success rate on recommended stocks.

Currently, the analyst consensus on Dianthus Therapeutics is a Strong Buy with an average price target of $130.63.

Based on Dianthus Therapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $463 thousand and a GAAP net loss of $40.83 million. In comparison, last year the company earned a revenue of $1.16 million and had a GAAP net loss of $29.51 million